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Abstract
Introduction: The term "intracystic papillary ductal carcinoma in situ" has recently changed and is
now more appropriately referred to "intracystic papillary carcinoma". Intracystic papillary
carcinoma in men is an extremely rare disease with only a few case presentations published in the
literature so far.
Case presentation: We discuss a case of a 44-year-old Caucasian man with an intracystic
papillary carcinoma treated with simple mastectomy, sentinel lymph-node biopsy and contralateral
risk-reducing mastectomy. These were followed by adjuvant radiotherapy of the breast.
Conclusion:  Triple assessment (i.e. clinical examination and radiological and histological
assessment) with a high level of clinical suspicion is necessary to diagnose intracystic papillary
carcinoma in men due to its rarity. Furthermore, genetic testing and risk-reducing mastectomy
should also be considered in cases of a strong family history for male breast cancer.
Introduction
Breast carcinoma in men is rare; it represents 0.6% of all
breast carcinomas and less than 1% of all malignancies in
men. Male breast cancer has an incidence of one per
100,000 per annum. Overall survival rates for men with
breast carcinoma, stratified by stage of disease, are lower
than for women with breast carcinoma. However, these
differences are most likely due to the higher age distribu-
tion of male patients and the lower life expectancy of men
in the general population [1].
Intracystic papillary carcinoma (IPC) is a rare form of
breast cancer, accounting for 0.5–1% of all breast cancers.
It typically occurs in older women and has an excellent
prognosis. The reported 10-year survival rate for IPC is
100%, the recurrence-free survival rate is 96% and 77% at
2 and 10 years, respectively [2].
Here, we report the case of intracystic papillary ductal car-
cinoma in situ (DCIS)/carcinoma of the breast in a 44-
year-old male patient.
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Case presentation
A 44-year-old Caucasian man presented to the breast
clinic with a 3-week history of a swelling in his left breast.
He also had a significant family history for breast cancer
including a maternal grandmother, two of his maternal
aunts and a maternal first cousin diagnosed with breast
cancer. On examination, a well-circumscribed, 2.5 cm
swelling was palpable within an area of gynecomastia on
the left chest wall. Sonographically, a cystic mass with
internal echoes was present without posterior acoustic
shadowing. Aspiration of the lesion revealed uniformly
blood-stained fluid and a residual swelling persisted.
Cytology analysis of the aspirate confirmed the presence
of atypical cells. Mammography showed a circumscribed
mass in the sub-areolar region of the left breast with par-
tially obscured margins. An irregular outline was noted on
cranio-caudal view, but no spiculation or suspicious inter-
nal micro-calcifications were found. A core biopsy of the
lesion revealed atypical ductal hyperplasia, but no evi-
dence of malignancy was seen. In view of the atypical cells
and residual swelling the lesion was excised.
Histological analysis revealed a lesion 2.5 cm × 1.8 cm ×
1.2 cm in size. The lesion comprised a papillary and solid
proliferation of atypical cells within a large cystic space
with a thick fibrous capsule (Figures 1, 2, 3) Haemorrhage
was also noted within the cyst with changes consistent
with the prior biopsy. The margins were clear; there was
no evidence of stromal or fibrovascular invasion. The
lesion displayed features of papillary DCIS and a diagno-
sis of intracystic papillary DCIS was made. Immunohisto-
chemistry showed oestrogen receptor (ER) and
progesterone receptor (PR) positivity.
Completion left mastectomy with sentinel lymph-node
mapping was carried out. Contralateral risk-reducing mas-
tectomy was also performed in view of the strong family
history for breast cancer. No evidence of further disease
was detected in the mammary tissue and the sentinel node
was clear. Adjuvant radiotherapy (40 Gy in 25 fractions)
Hematoxylin-eosin stain in excised tumours Figure 1
Hematoxylin-eosin stain in excised tumours. Low-
power view illustrating a 2.5 × 1.8 × 1.2 cm lesion within a 
large cystic space surrounded by a thick fibrous capsule. 
Haemorrhage was also noted within the cyst with changes 
consistent with the prior biopsy.
Hematoxylin-eosin stain in excised tumours, At higher  power, a papillary and solid proliferation of atypical cells of a  uniform population were observed Figure 2
Hematoxylin-eosin stain in excised tumours, At 
higher power, a papillary and solid proliferation of 
atypical cells of a uniform population were observed. 
Fibrovascular cores were well visualized.
Hematoxylin-eosin stain in excised tumours, At higher  power, a papillary and solid proliferation of atypical cells of a  uniform population were observed Figure 3
Hematoxylin-eosin stain in excised tumours, At 
higher power, a papillary and solid proliferation of 
atypical cells of a uniform population were observed. 
Fibrovascular cores were well visualized.Journal of Medical Case Reports 2009, 3:13 http://www.jmedicalcasereports.com/content/3/1/13
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was advised due to tumour extension close to deep mar-
gin.
Due to his significant family history for breast cancer,
genetic testing was offered. Breast-cancer gene 2 (BRCA2)
mutation had been identified in a maternal aunt recently
on the exon 24 insertion called c9481_9482insA. It was
very likely that this patient was a carrier of this BRCA2
mutation, which poses a small risk for him to develop
prostate cancer. He was therefore advised to undergo pros-
tate-specific antigen (PSA) blood testing on a yearly basis.
Discussion
IPC is a rare malignancy of the breast; however, a rela-
tively higher incidence range of 5–7.5% has been reported
in men [3-5]. IPC in men is usually reported among those
of an older age group (68 to 84 years) [4,6-9]; however, in
our patient, IPC developed at a significantly younger age,
which might be due to this patient likely carrying the
BRCA2 mutation. The prognosis for this type of tumour is
excellent [3,7]. In a study of 77 patients with IPC all
patients were alive 10 years after their diagnosis and
metastases occurred only in 4% of patients, but none of
the patients with low-grade tumours were in this group
[10].
The terminology applied to describe papillary breast
lesions in the literature is relatively confusing. The tradi-
tional term "intracystic papillary carcinoma" generally
refers to a localized lesion, in situ in a cystically dilated
duct. Given the often marked stromal response surround-
ing these lesions, the distinction between in situ and inva-
sive papillary carcinoma can be very difficult to make.
Therefore, IPC had been divided it into three subgroups,
which seems to correlate with the prognosis: IPC alone,
IPC plus DCIS, and IPC with invasion [5]. In this manner,
the term "papillary DCIS" would refer to a more diffuse
process that involves multiple ducts as opposed to a local-
ized lesion [5].
Recently, Hill et al., using myoepithelial cell staining, sug-
gest a spectrum of progression from in situ disease to inva-
sive disease, signifying that what appears to be DCIS on
histology may potentially cause distant metastases [11].
The lack of an intact basal myoepithel cell layer can be
identified by calponin, smooth-muscle myosin heavy
chain (SMM-HC) cytoplasmic stains and by p63 nuclear
stains. This "gold standard" method has a relatively high
sensitivity and denotes the invasiveness of the tumour
cells in malignant papillary breast lesions [11].
The diagnosis of IPC of the male breast should be made
carefully. Triple assessment is essential and the goal is to
achieve a preoperative diagnosis prior to surgery. The radi-
ological diagnosis of IPC is relatively challenging. The typ-
ical sonographical appearance of IPC is a hypoechoic area
with soft tissue echoes projecting from the wall of the cyst
[6,7]. However, a relatively large amount of variation
exists on ultrasounds from an intraductal (which might be
associated with ductal dilatation) and a predominantly
solid pattern with the intraductal or intracystic mass
totally filling the duct [12]. Importantly, IPCs are highly
vascular tumours demonstrating a characteristic flow pat-
tern on colour-flow studies, which are sensitive to identi-
fying even very small IPCs. A distinct vascular pedicle can
be identified within the central core with branching ves-
sels arborising within the mass [12].
The mammographic appearance of IPCs is less specific.
Small IPCs are often mammographically negative, while
larger lesions may resemble any other focal well-circum-
scribed dense mass on mammography [12]. Both can
cause a minimal to moderate duct dilatation in a tapering
band-like density pattern from the nipple towards the
parenchyma. In addition, one report suggested the use of
pneumocystography [8], and another MRI [9], in combi-
nation with mammography and ultrasound to diagnose
IPC.
Fine-needle aspiration cytology and core biopsy are usu-
ally performed; however, the false negative results with
cytology are relatively frequent [13]. Therefore, excisional
biopsy should be carried out in all cystic lesions of the
male breast which are suspicious on any of the above
diagnostic modalities.
There are no clear guidelines about the management of
IPC, which is due to various factors. On one hand, IPC is
a rarity; on the other hand, the histopathological classifi-
cation and detection of invasiveness in IPC is rather con-
fusing [3,5]. In a recent review, Grabowski et al. [3]
confirmed that surgery is the mainstay of treatment,
which can be either conservation or mastectomy. Since
the prognosis of IPC is excellent with low locoregional
and distant recurrence rates, mastectomy is usually not
necessary, unless it is technically unavoidable [3]. Axillary
node metastasis can occur in up to 14% of the cases [3];
therefore, an axillary staging procedure or clearance is rec-
ommended by most authors [3,4,9]. Others argue that
IPC should be generally regarded as an in situ disease;
therefore axillary surgery is not recommended by these
authors [6-8]. There has been no clear indication for adju-
vant endocrine therapy, even among patients with oestro-
gen-receptor-positive tumours. The addition of hormonal
treatment does not appear to have impacted the outcome
[3]. On the contrary, Fayanju et al. recently reviewed the
usual adjuvant treatment applied for IPC and found that
patients with DCIS or microinvasive disease in association
with IPC were more likely to receive radiotherapy and
tamoxifen [14].Publish with BioMed Central    and   every 
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Between 4% and 40% of male breast cancers might result
from autosomal dominant mutations, primarily BRCA1
or BRCA2 mutations [15]. Due to the high risk to our
patient, contralateral risk-reducing mastectomy was also
carried out. This reduces the incidence of contralateral
breast cancer by approximately 95% but will not have an
impact on overall survival of the patient [15].
Conclusion
Triple assessment with a high level of clinical scepticism-
scepticism is necessary to diagnose IPC in a man, due to
the rarity of the condition. The treatment of choice for this
tumour is ample local excision. However, genetic testing
and risk-reducing mastectomy should also be considered
in cases of male breast cancer with a strong family history.
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